Physician profile
Albert Bundy
NPI 1194709378
$729.40
in general payments reported to CMS, 2019-2025
16 companies · $99.99 in 2025
The $99.99 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.22 · 2020: $83.89 · 2021: $87.13 · 2022: $134 · 2023: $139 · 2024: $94.29 · 2025: $99.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $233 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $233.13 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $144.00 | 2021-2025 | Ilumya |
| Abbvie INC. | $105.75 | 2020-2023 | Skyrizi |
| Almirall LLC | $96.82 | 2022 | |
| Smith+Nephew, INC. | $83.63 | 2023-2024 | Grafix Pl |
| Pfizer INC. | $54.52 | 2019-2021 | |
| Leo Pharma INC. | $41.55 | 2024 | Adbry |
| Regeneron Healthcare Solutions, INC. | $37.89 | 2023 | Libtayo |
| Prugen, INC. Pharmaceuticals | $31.48 | 2019 | |
| Genzyme Corporation | $19.68 | 2023 | |
| Amgen INC. | $19.13 | 2020 | |
| Allergan, INC. | $18.86 | 2022 | |
| Genentech USA, INC. | $17.76 | 2019 | |
| Galderma Laboratories, L.P. | $17.23 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.13 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.60 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Bundy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.